Pivotal bioVenture Partners
Peter Bisgaard joined Pivotal in 2017. He is also Managing Director of Nan Fung Life Sciences. Peter brings more than 17 years of experience in biotech VC investing. He was a Senior Partner at Novo Ventures and has been with Novo Ventures (US) Inc. since 2009. As part of Novo Ventures’ senior team he was responsible for overall investment and portfolio strategy as well as ongoing development of Novo Ventures’ team in the US.
Peter was with Novo Ventures since 2001 in Denmark. Prior to Novo Ventures he was with McKinsey & Co. and the Firm’s Corporate Finance and Strategy Practice. Peter is the member of —or has been a member of— the Board of Directors of a number of public and private biotech and medtech companies including RA Pharmaceuticals (NASDAQ:RARX), Nevro Corp (NYSE:NVRO), Alder Biotherapeutics (NASDAQ:ALDR), Otonomy (NASDAQ:OTIC), HTG Molecular Diagnostics (NASDAQ:HTGM), Eargo Inc, Entasis Therapeutics, Outpost Medicine, Bolt Therapeutics and Inozyme Inc.
Peter has an M.Sc. in Engineering from the Technical University of Denmark and has a post graduate degree in Mathematical Modeling in Economics by the European Consortium for Mathematics in the Industry.
This person is not in the org chart
This person is not in any offices
Pivotal bioVenture Partners
Pivotal bioVenture Partners China, a member of Nan Fung Life Sciences, is a venture capital firm specializing in venture building in the life sciences industry. Its investment strategy is centered on identifying promising innovative products and technologies and bringing them to serve the growing unmet medical needs in Greater China region by building new ventures. Its investment areas include therapeutics, medical devices, and medical services. The Pivotal China team includes experienced life science investors and entrepreneurs with successful track records of venture building and investing.